Wataru Fukuokaya
0000-0003-1044-912X
Jikei University School of Medicine
32 papers found
Refreshing results…
Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer
The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer
Differences in sex hormone recovery profile after cessation of 12‐week gonadotropin‐releasing hormone antagonist versus agonist therapy
Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Nonmuscle Invasive Bladder Cancer
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer
Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall Survival
Prognostic role of the systemic immune–inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
Bladder cancer invasion along a tension‐free vaginal mesh
Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Supine extraperitoneal laparoscopic nephroureterectomy without patient repositioning
Reply to Cengiz Beyan and Esin Beyan. Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer. Int J Clin Oncol 97(2), 3–4, 2020
Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: A propensity score-matched analysis
Red cell distribution width – an exploratory novel objective prognostic biomarker study in renal conserving endoscopic upper tract urothelial carcinoma (RC-EUTUC) management
Risk stratification for the prediction of overall survival could assist treatment decision‐making at diagnosis of castration‐resistant prostate cancer: a multicentre collaborative study in Japan
Missing publications? Search for publications with a matching author name.